Key Stats for Thermo Fisher Stock
- Current Price: $605.69
- Target Price (Mid): ~$839
- Street Target: ~$645
- Potential Total Return: ~39%
- Annualized IRR: ~8% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Thermo Fisher Scientific (TMO) picked up two bullish analyst calls in a single week, and both landed with the stock already near the top of its 52-week range. On September 3, CLSA started coverage at Outperform with a $748 target. Five days later, UBS upgraded the stock to Buy from Neutral and moved its target to $730 from $540.
The stock closed at $605.69 on September 9, up just 0.44% on the day, a muted reaction to targets that imply 20% or more of upside. Bernstein kept a Hold on the name the same week, so the Street is genuinely split. That gap, between what the boldest banks project and what the market will pay, is the story, and the company’s own consensus tells the sober version.
Why UBS Flipped After Sitting on the Sidelines
This was a bank rated Neutral at $540, and it moved to Buy at $730 as coverage transferred to a new analyst, so the person who defended the cautious rating is no longer the one writing the note. The reasoning was specific rather than promotional: UBS argued Thermo Fisher can return to a durable 5% to 6%-plus organic growth in 2027 without a recovery in academic and government funding, one of the softest parts of the business through early 2026.
UBS assumes only low-single-digit stability in academic and government, roughly 10% of revenue, and still reaches durable mid-single-digit growth from pharma and biotech demand, bioprocessing, reshoring, AI-driven research spending, and share gains. The bull case no longer depends on the hardest variable to forecast turning up.
The trigger was the July 23 earnings report, where Thermo Fisher beat on organic growth and raised full-year guidance to $24.93 to $25.33 in adjusted EPS. CEO Marc Casper’s framing on that call was that innovation pulls funding even in tight budgets: “if you have really relevant innovation, customers get money.” He pointed to Analytical Instruments, which grew organically 7% with an operating margin up 420 basis points on new Orbitrap launches and semiconductor-driven electron microscopy bookings.
See historical and forward estimates for Thermo Fisher stock (It’s free!) >>>
What the Market Is Still Pricing In
Thermo Fisher trades at 23.06x NTM earnings and 20.25x EV/EBITDA, both back in the upper half of the range the stock has held since early 2024. Shares have recovered from a 31.45% drawdown that bottomed on May 15, 2026, and now trade near the top of that 52-week range.
IQVIA trades at 18.84x forward earnings and Charles River at 22.65x, while faster-growing Medpace commands 31.76x and Illumina 35.95x. Thermo Fisher sits in the middle of a group where scale, diversification, and margin resilience earn a step up, though not an unlimited one.
See how Thermo Fisher performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $605.69
- Target Price (Mid): ~$839 by year-end 2030
- Potential Total Return: ~39% over 4.3 years
- Annualized IRR: ~8% / year
See analysts’ growth forecasts and price targets for Thermo Fisher stock (It’s free!) >>>
Revenue drivers: a return to ~5% organic growth led by the pharma and biotech recovery, plus layered contribution from Clario and the acquired Solventum filtration and separation business
Margin driver: operating leverage lifting net income margin toward ~21% via PPI productivity and synergies
Primary risk: the academic and government end market, which management has declined to call recovered
The upside case is that pharma and biotech accelerate while academic and government finally inflects, pushing toward the high scenario near $1,260. The downside is that the multiple compresses as growth stays mid-single-digit, leaving an investor to collect earnings growth with no help from the rating.
UBS and CLSA underwrite a re-rating on top of earnings growth. The Street’s 12-month mean target of $645 sits just 6.5% above the current price, closer to the model than to the bank headlines. Two credible numbers, one built on multiple expansion and one on compounding at today’s P/E, and they do not agree.
Conclusion
The next test is the Q3 2026 report, expected in late October. Management guided to about 4% organic growth for the second half. A print at or above that, with clinical research authorizations still climbing, would validate the UBS thesis that Thermo Fisher can grow without an academic and government recovery. A number below 4% would tell you the bulls got ahead of the business. The targets say $730 and $748. The model and the Street mean say wait for the print to prove it.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Thermo Fisher?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Thermo Fisher, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thermo Fisher alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Thermo Fisher on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
